NovaBay Reports Positive Results of Ophthalmic Solution

NovaBay Pharmaceuticals announced the results of a phase II clinical study for the treatment of adenoviral conjunctivitis.

NovaBay Pharmaceuticals, Inc., a biotechnology company focused on developing its proprietary and patented Aganocide compounds, announced beneficial results from a Phase II clinical study of NVC-422 ophthalmic solution, used for the treatment of adenoviral conjunctivitis, a contagious ocular infection commonly known as 'pink eye'.

The study randomised 452 patients and reportedly improved clinical signs, symptoms and microbiological findings in 38% of patients infected with adenovirus serotypes associated with epidemic kerato conjunctivitis.

Epidemic kerato conjunctivitis is a contagious eye infection affecting both the cornea and the conjunctiva.